問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Chung Shan Medical University Hospital

Division of Thoracic Medicine

List

96Cases

2022-10-01 - 2029-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-03-01 - 2026-02-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2022-09-30 - 2026-04-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-05-31 - 2026-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting1Sites

Terminated5Sites

2021-12-23 - 2024-12-31

Phase III

Completed
A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype

  • Condition/Disease

    Asthma

  • Test Drug

    GSK3511294

Participate Sites
9Sites

Recruiting9Sites

2025-09-22 - 2029-03-18

Phase II

Active
A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

  • Condition/Disease

    Metastatic Non-Small Cell Lung Cancer (LIBRA)

  • Test Drug

    Injection

Participate Sites
9Sites

Recruiting9Sites

2023-07-01 - 2027-04-20

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2023-01-30 - 2026-04-24

Phase III

Active
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

  • Condition/Disease

    Advanced or Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    Ceralasertib (AZD6738)Durvalumab (MEDI4736)

Participate Sites
8Sites

Not yet recruiting8Sites

2020-09-22 - 2024-03-29

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2025-08-31 - 2028-08-31

Phase I/II

Active
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Injection

Participate Sites
3Sites

Recruiting3Sites

1 3 4 5 6 7 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB